This Trump policy could slow cancer cures worldwide
The article discusses concerns over President Trump's proposed drug pricing policy, which aims to tie U.S. prices to those set by foreign governments. Critics argue that this 'most favored nation' policy could undermine pharmaceutical innovation and limit patient access to new treatments. The author advocates for a different approach that pressures other countries to contribute fairly to the global pharmaceutical ecosystem.
- ▪Trump's policy could import foreign price controls, negatively impacting U.S. drug prices.
- ▪Patients in countries like Japan and those in Europe often have limited access to new medicines compared to Americans.
- ▪A University of Chicago analysis suggests that the proposed policy could halve U.S. research spending, leading to fewer new medicines.
Opening excerpt (first ~120 words) tap to expand
When my mother died of colon cancer, I saw firsthand the devastation that comes when treatment options run out. For decades, I’ve worked to spare others that same fate — helping patients around the world get the right medicine at the right time. That’s why I’m deeply concerned by President Donald Trump’s push to tie U.S. drug prices to those set by foreign governments. Recommended Stories Trump’s ‘yes men’ are driving Republicans toward disaster Cuba’s regime has no military answer to American power No, Israel doesn’t run America The concern isn’t the goal itself. Trump is right that other wealthy nations have long benefited from American pharmaceutical innovation without paying their fair share for it.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
